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Objectives. We sought to evaluate the effect of clinical factors on
recovery of atrial function after cardioversion for atrial fibrilla-
tion.
Background. Lack of effective mechanical atrial function
(EMAF) after cardioversion of atrial fibrillation predisposes to
thromboembolic complications and delays improvement in func-
tional capacity.
Methods. Fifty-two patients underwent cardioversion (group I,
electrical cardioversion, n 5 40; group II, pharmacologic or
spontaneous cardioversion, n 5 12) for atrial fibrillation. Serial
transmitral inflow Doppler variables were recorded after cardio-
version until EMAF (atrial filling velocity >0.50 m/s) was seen.
Clinical variables (age, duration of atrial fibrillation, left ventric-
ular ejection fraction, left atrial diameter, underlying cardiovas-
cular disease, antiarrhythmic drug therapy and mode of cardio-
version) were tested for an association with the outcomes of
recovery of atrial function by day 3 and day 7.
Results. Effective mechanical atrial function recovered in 68%
of patients by day 3 and in 76% by day 7 after cardioversion. The
mode of cardioversion was significantly associated with recovery
of atrial function by day 3 in bivariate and multivariate analyses
(odds ratio 0.12, 95% confidence interval 0.01 to 1.0, for electrical
cardioversion). None of the variables had an association with
recovery of atrial function by day 7. Group I patients took a longer
time to recover atrial function than group II patients (p 5 0.012).
In addition, group I patients had a significantly lower peak atrial
filling velocity (mean [6SD] 0.39 6 0.19 m/s vs. 0.56 6 0.16 m/s)
and a higher early filling to atrial filling velocity ratio (2.5 6 1.2
vs. 1.5 6 0.5) after cardioversion.
Conclusions. A high proportion of patients recover EMAF
within 1 week after cardioversion. Patients who undergo electrical
cardioversion display a greater degree and a longer duration of
mechanical atrial dysfunction than those who convert pharmaco-
logically or spontaneously.
(J Am Coll Cardiol 1997;30:481–6)
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Atrial mechanical dysfunction after cardioversion for atrial
fibrillation has received considerable attention in the last few
years (1). Its significance is corroborated by the occurrence of
thromboembolic events after cardioversion, despite exclusion
of left atrial appendage thrombus by transesophageal echocar-
diography before cardioversion (2–4). These thromboembolic
events, which occur in the absence of preexisting left atrial
appendage clot, are believed to be causally related to atrial
dysfunction after cardioversion, which predisposes to throm-
bus formation (2). Because normal atrial contraction is be-
lieved to lag behind conversion to sinus rhythm by up to a few
weeks (1), patients undergoing cardioversion are often antico-
agulated for a prolonged period.
Restoration of normal atrial contraction may be related to
several clinical factors, such as patient age, mode of cardiover-
sion, left atrial size, left ventricular function, associated car-
diovascular disease and myocardial depressant effect of pro-
phylactic antiarrhythmic therapy (2). The effect of these
clinical variables on recovery of effective mechanical atrial
function (EMAF) has not been adequately assessed. This study
was conducted to examine the role of clinical variables in
recovery of EMAF. We hypothesized that electrical cardiover-
sion would be associated with a longer duration and greater
degree of left atrial mechanical dysfunction than pharmaco-
logic or spontaneous cardioversion.
Methods
Study patients. Hemodynamically stable patients referred
for cardioversion for atrial fibrillation between May 1995 and
March 1996 were considered for inclusion in this study. No
exclusions were made based on age, gender, concomitant
disease states, ventricular function, cause or duration of atrial
fibrillation or medical therapy. Patients who had any docu-
mented evidence of atrial flutter on the electrocardiogram
(ECG) and those who were unable to follow up for logistic
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reasons were not included. Of 54 patients considered for
participation in the study, two were excluded because of failure
of cardioversion (n 5 1) or predominant atrial flutter on the
ECG (n 5 1). Thus, the study group consisted of 52 patients
successfully cardioverted to sinus rhythm. Patients were clas-
sified as group I if they underwent electrical cardioversion (n 5
40) and group II if they cardioverted with medications (n 5 10)
or spontaneously (n 5 2).
The baseline characteristics of the study group are shown in
Table 1. Underlying cardiovascular diseases were present in
85% of the patients and included one or more of the following:
hypertension (58%), ischemic or nonischemic dilated cardio-
myopathy (21%), coronary artery disease (17%), significant
valvular disease (8%), hypertrophic cardiomyopathy (4%) or
pericardial disease (4%). In eight patients (15%), no structural
cardiovascular disease was identified. A specific precipitating
factor was identified in only one patient (2%) who had atrial
fibrillation after cardiac surgery. At the time of enrollment,
patients were on the following medications for ventricular rate
control or antiarrhythmic effect: digoxin (n 5 17, 33%),
beta-adrenergic blocking agents (n 5 31, 60%), calcium chan-
nel blocking agents (verapamil or diltiazem, n 5 10, 19%),
amiodarone (n 5 10, 19%), flecainide (n 5 4, 8%) or
propafenone (n 5 1, 2%).
The duration of atrial fibrillation was ,28 days in 14
patients; all of these patients presented with their first episode
of atrial fibrillation. In the other 38 patients, the duration of
atrial fibrillation was $28 days (28 days to 3 months in 12
patients [32%], .3 to 6 months in 11 [29%], .6 to 12 months
in 9 [24%], .12 to 24 months in 3 [8%], .24 months in 1 [3%]
and unknown in 2 [5%]).
The protocol was approved by the Institutional Review
Board of the Alton Ochsner Medical Foundation. All patients
provided written informed consent. All procedures were con-
ducted in accordance with institutional guidelines.
Cardioversion. The decision to perform electrical or phar-
macologic cardioversion was made on the basis of the clinical
situation, in consultation with the referring cardiologist, and
was independent of enrollment into the study protocol. For
electrical cardioversion, fasting patients received intravenous
sedation with methohexital sodium (total dose 0.5 to 1.5 mg/kg
body weight). A Physio-Control (LIFEPAK 8) direct current
cardioverter was used in all patients. Thirty-two patients (80%)
cardioverted with a single electrical shock; multiple shocks
were required in the other eight patients. The total amount of
electrical energy used for cardioversion was 379 6 285 J per
patient.
For pharmacologic cardioversion, patients were hospital-
ized and monitored in a telemetry setting. Telemetry monitor-
ing technicians notified the investigators as soon as cardiover-
sion to normal sinus rhythm occurred, and they obtained ECG
rhythm strips for confirmation of normal sinus rhythm. Car-
dioversion occurred during treatment with the following med-
ications: oral sotalol (n 5 3), oral quinidine (n 5 1), intrave-
nous procainamide (n 5 2), intravenous metoprolol (n 5 3) or
intravenous diltiazem (n 5 1). In two patients, cardioversion to
sinus rhythm occurred before any medications were instituted.
Echocardiographic studies. Transthoracic two-dimensional
imaging and pulsed wave Doppler echocardiographic studies
were obtained in all patients using a Hewlett-Packard Sonos
1000 or 1500 ultrasound machine equipped with 2.5- and
3.5-MHz phased array transducers. Transmitral inflow veloci-
ties were recorded from the apical four-chamber view with the
sample volume positioned between the tips of the mitral valve
leaflets. To ensure standardization, all studies were performed
in the morning hours with the patient in the supine position
after 10 min of rest. To minimize technical sampling errors, we
attempted to have the same sonographer perform studies
whenever possible. Studies were recorded on S-VHS videotape
for later review by one of the investigators who had no
Abbreviations and Acronyms
A 5 atrial wave filling velocity
E 5 early wave filling velocity
E/A 5 ratio of early transmitral flow velocity to atrial flow velocity
ECG 5 electrocardiogram, electrocardiographic
EMAF 5 effective mechanical atrial function
Table 1. Baseline Characteristics of Patients Undergoing
Cardioversion for Atrial Fibrillation
Clinical Characteristic
All
Patients
(n 5 52)
Group I
(n 5 40)
Group II
(n 5 12)
Age (yr)* 67.6 6 12.2 68.8 6 11.4 63.0 6 14.5
Gender (%)
Male 55 53 58
Female 45 47 42
Duration of atrial
fibrillation (%)
,28 days 27 23 42
$28 days 73 77 58
Underlying cardiovascular
disease (%)†
Present 85 85 83
Absent 15 15 17
Use of antiarrhythmic drugs
at enrollment (%)‡
Present 71 71 75
Absent 29 29 25
Mode of cardioversion (%)
Electrical (group I) 78 — —
Nonelectrical (group II) 22§
Left ventricular ejection
fraction (%)
$50% 79 75 92
,50% 21 25 8
Left atrial diameter (cm)* 4.5 6 0.7 4.6 6 0.7 4.3 6 0.9
*Mean 6 SD. †Including hypertension. ‡Including beta-blockers and first-
generation calcium channel blockers (verapamil and diltiazem). §Includes 10
patients who underwent pharmacologic cardioversion and two patients who
cardioverted spontaneously. No significant difference was seen between the
groups for any of the clinical characteristics.
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knowledge of the patient’s clinical background. An average of
5 to 7 beats was studied with pulsed wave recording of the
transmitral flow velocities. Peak velocities and time velocity
integrals of early filling (E) and atrial filling (A) waves were
determined on each study.
Assessment of mitral inflow variables was performed on the
day of cardioversion (within 6 h after cardioversion) and on
days 1, 3 and 7. In each patient, echocardiographic follow-up
was continued until such time as one of the following end
points was reached: recovery of EMAF (i.e., atrial filling wave
velocity $0.5 m/s [n 5 37, 71%]) (1), recurrence of atrial
fibrillation (n 5 5, 10%) or completion of the study protocol 7
days after cardioversion (n 5 8, 15%). Two patients (4%) were
lost to follow-up.
Left ventricular ejection fraction was estimated from the
parasternal long- and short-axis views and apical four- and
two-chamber views. Left atrial dimension was measured at
end-systole in the parasternal long-axis view.
Effective mechanical atrial function. This was assessed by
transthoracic Doppler echocardiography in accordance with
Manning et al. (1) and defined as the presence of atrial filling
waves with a peak velocity $0.5 m/s. Thus, by definition, the
end point of recovery of EMAF is a composite of persistence
of normal sinus rhythm and achievement of adequate atrial
filling wave velocity after cardioversion. In contrast, failure to
recover EMAF represents either a lack of adequate A wave
velocity with normal sinus rhythm, or recurrence of atrial
fibrillation, which precludes satisfactory atrial filling waves.
Independent variables and outcomes. Independent clinical
variables tested for an association with recovery of EMAF are
age, duration of atrial fibrillation (,28 days or $28 days),
left ventricular ejection fraction (,50% or $50%), mode
of cardioversion (group I, electrical cardioversion; or group
II, pharmacologic or spontaneous cardioversion), left atrial
diameter, use of antiarrhythmic medications (including beta-
blockers and calcium channel blockers) and presence of asso-
ciated cardiovascular disease, including hypertension. Out-
comes were prospectively defined and included recovery of
EMAF by day 3 and recovery of EMAF by day 7.
Statistical analysis. Comparisons between continuous and
categoric variables were performed using the unpaired t test.
For comparisons of categoric variables, frequency tables and
chi-square analyses were used. To evaluate the effect of
clinically relevant variables on the outcomes of recovery of
EMAF by day 3 and recovery of EMAF by day 7 after
cardioversion, bivariate analysis was initially performed using
logistic regression. Odds ratios and confidence intervals were
calculated for categoric variables. To assess the independent
effect of variables on the outcomes, backward stepwise regres-
sion was used. Life-table analysis was used to assess the
difference between group I and group II with respect to time to
recovery of effective atrial mechanical contraction.
All analyses were performed using the BMDP version 7.0
software. Data are expressed as mean value 6 SD for contin-
uous variables, and as percentages for categoric variables.
Statistical significance was established at p , 0.05.
Results
Clinical characteristics. Patients in groups I and II were
similar with respect to age, duration of atrial fibrillation,
presence of coexisting cardiovascular diseases, left ventricular
ejection fraction, left atrial diameter and use of antiarrhythmic
medications at the time of enrollment (Table 1).
Recovery of EMAF after cardioversion. Using life-table
analysis, earlier recovery of EMAF was seen in patients who
cardioverted pharmacologically or spontaneously compared
with those who underwent electrical cardioversion (p 5 0.01)
(Fig. 1). Between the two groups, the difference in the propor-
tion of patients with recovery of EMAF is more pronounced up
to day 3 and begins to taper off on day 7. Fifty-two percent of
all patients recover EMAF by day 1, 68% by day 3 and 76% by
day 7.
Clinical variables affecting recovery of atrial function by
day 3. Thirty-four (68%) of the 50 patients who completed
follow-up recovered EMAF by day 3. This included 23 (61%)
of 38 patients from group I and 11 (92%) of 12 patients from
group II. On bivariate analyses, age, duration of atrial fibrilla-
tion, left ventricular ejection fraction, presence of cardiovas-
cular disease, use of antiarrhythmic therapy or left atrial
diameter did not show any significant association with recovery
of EMAF by day 3. The mode of cardioversion was significantly
associated with this outcome; thus, patients who underwent
electrical cardioversion had an odds ratio of 0.12 for recovery
of EMAF by day 3, indicating that electrical cardioversion,
compared with pharmacologic or spontaneous cardioversion,
was associated with a lower probability of achievement of
EMAF by day 3. Odds ratios and confidence intervals were not
significant for any of the other categoric variables (Table 2).
On multivariate analysis, the mode of cardioversion remained
significantly associated with recovery of EMAF by day 3, when
adjusted for age, presence of cardiovascular disease or use of
antiarrhythmic therapy. However, when adjusted for duration
Figure 1. Recovery of EMAF after cardioversion (p 5 0.01 for group
I vs. group II). Circles 5 all patients; squares 5 group I; triangles 5
group II.
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of atrial fibrillation, left ventricular ejection fraction or left
atrial diameter, the association between mode of cardioversion
and recovery of EMAF by day 3 was no longer statistically
significant.
Clinical variables affecting recovery of EMAF by day 7. By
day 7, 76% of all patients recovered EMAF. This group
included 27 (71%) of the 38 electrically cardioverted patients
who completed the study and 11 (92%) of 12 pharmacologi-
cally or spontaneously cardioverted patients. None of the
independent variables used in this analysis had an association
with the outcome of recovery of EMAF by day 7 on bivariate
or multivariate analysis. The odds ratios and 95% confidence
intervals for categoric variables are shown in Table 2.
Comparison of pulsed wave Doppler transmitral record-
ings after cardioversion. A comparison between group I and
group II with respect to mitral inflow variables obtained within
6 h after cardioversion is shown in Table 3. Group I patients
who underwent electrical cardioversion showed a significantly
lower peak atrial filling wave velocity (A), a lower time velocity
integral of atrial filling wave and a higher ratio of peak early
filling velocity to peak atrial filling velocity (E/A ratio) com-
pared with group II. No significant difference was found in the
peak early filling wave velocity (E) or the time velocity integral
of the early filling wave between the groups.
Discussion
Four main findings emerge from our study. First, a large
proportion of patients who undergo cardioversion for atrial
fibrillation recovered EMAF early after cardioversion. Ap-
proximately one in five patients recovered EMAF within 6 h
after cardioversion. More than half of all patients recovered
EMAF by the first day after cardioversion and more than
three-fourths recovered EMAF by 1 week after cardioversion.
Furthermore, 11 (92%) of 12 patients who underwent phar-
macologic or spontaneous cardioversion recovered EMAF by
day 3. Second, of all the clinical variables tested on bivariate or
multivariate analysis, only the mode of cardioversion was seen
to have any impact on recovery of atrial function. Thus,
patients who underwent electrical cardioversion were signifi-
cantly less likely to recover EMAF by the third day after
cardioversion (odds ratio 0.12) compared with those who
cardioverted pharmacologically or spontaneously. This effect
remains significant when adjusted for patient age, presence of
underlying cardiovascular disease or use of antiarrhythmic
drug therapy; however, it is no longer significant when adjusted
for left ventricular ejection fraction, left atrial diameter or
duration of atrial fibrillation. Third, the effect of the mode of
cardioversion on recovery of EMAF is not statistically signifi-
cant at 1 week after cardioversion, implying that the possible
detrimental effect of electrical current on atrial function is an
early phenomenon and wears off between 3 and 7 days after
cardioversion. Accordingly, among the two groups of patients,
the greatest difference in the proportion of patients recovering
EMAF is seen in the first 3 days after cardioversion (Fig. 1).
Fourth, mitral inflow variables recorded within 6 h after
cardioversion show a significantly lower peak atrial filling
velocity, a lower time velocity integral of the atrial filling wave
and a higher early filling to atrial filling peak velocity ratio
(E/A ratio) in the electrically cardioverted patients, implying a
greater degree of atrial dysfunction in these patients. This is
consistent with the delayed recovery of atrial function in
electrically cardioverted patients.
Clinical variables affecting atrial function after cardiover-
sion. Several investigators previously attempted to identify
factors that affect the recovery of atrial function after cardio-
version for atrial fibrillation. Manning et al. (5) demonstrated
that immediately after cardioversion and at 24 h and 1 week
after cardioversion, atrial mechanical function is better in
patients with atrial fibrillation ,2 weeks in duration than in
those with atrial fibrillation .6 weeks in duration. Although
there was no difference in the left atrial diameter between the
groups with atrial fibrillation of “brief” (,2 weeks), “moder-
ate” (2 to 6 weeks) or “prolonged” (.6 weeks) duration, other
patient characteristics such as age, left ventricular ejection
fraction, underlying cardiac diseases, concomitant antiarrhyth-
mic therapy and mode of cardioversion were not separately
reported for the three groups. Any one or combination of these
Table 3. Mitral Inflow Variables After Cardioversion: A
Comparison of Electrically Cardioverted (Group I) With
Pharmacologically or Spontaneously Cardioverted
(Group II) Patients
Mitral Inflow Variable Group I Group II p Value
Peak A wave velocity (m/s)* 0.39 6 0.19 0.56 6 0.16 0.01
Peak E wave velocity (m/s)† 0.85 6 0.24 0.83 6 0.25 0.83
Peak E/peak A (E/A ratio) 2.5 1.5 0.01
TVI A wave (m)‡ 0.05 6 0.03 0.08 6 0.02 0.04
TVI E wave (m)§ 0.13 6 0.05 0.12 6 0.05 0.99
*Atrial filling velocity. †Early filling velocity. ‡Time-velocity integral (TVI)
of atrial filling wave. §Time-velocity integral of early filling wave. E/A 5 ratio of
early transmitral flow velocity to atrial flow velocity.
Table 2. Effect of Clinical Variables on Recovery of Effective
Mechanical Atrial Function: Odds Ratios and 95%
Confidence Intervals
Clinical Variables OR 95% CI
Recovery of EMAF by day 3
Duration of atrial fibrillation $28 days 0.24 0.05–1.3
Left ventricular ejection fraction ,50% 0.48 0.12–2.0
Electrical cardioversion 0.12 0.01–1.0
Use of antiarrhythmic drugs 1.6 0.41–6.3
Presence of cardiovascular disease 1.0 0.16–6.4
Recovery of EMAF by day 7
Duration of atrial fibrillation $28 days 0.3 0.03–2.6
Left ventricular ejection fraction ,50% 0.3 0.06–1.8
Electrical cardioversion 0.3 0.03–3.0
Use of antiarrhythmic drugs 2.3 0.4–12.0
Presence of cardiovascular disease 0.8 0.2–5.8
CI 5 confidence interval; EMAF 5 effective mechanical atrial function;
OR 5 odds ratio.
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factors could conceivably influence recovery of EMAF inde-
pendent of the duration of atrial fibrillation. We included all of
these variables in our models using recovery of EMAF by day
3 and recovery of EMAF by day 7 after cardioversion as the
outcome measures. Interestingly, duration of atrial fibrillation
before cardioversion did not seem to affect the outcome
significantly.
In 78 patients with atrial fibrillation who underwent cardio-
version (electrical cardioversion in 60 patients, pharmacologic
in 18), Abascal et al. (6) found no significant difference in the
peak early filling and peak atrial filling velocities at 24 h after
cardioversion between the electrically and pharmacologically
cardioverted patients. They concluded that left atrial dysfunc-
tion after cardioversion is independent of the mode of cardio-
version. Their conclusion is in contrast to our findings, which
suggest that patients who require electrical cardioversion seem
to display greater atrial mechanical stunning. The difference
between their and our findings may be related to the duration
of atrial fibrillation in the two studies. All the patients in the
study reported by Abascal et al. had atrial fibrillation .4
weeks, whereas 27% of the patients in our study had atrial
fibrillation ,4 weeks.
Mattioli et al. (7) addressed the effect of underlying cardio-
vascular disease on recovery of effective atrial function in 60
patients with atrial fibrillation. Restoration of sinus rhythm
occurred spontaneously in 20 patients and was accomplished
pharmacologically in 40 patients. It was found that EMAF
recovered earlier in patients without cardiovascular disease
and in those with underlying hypertension only, compared with
those patients who had ischemic cardiomyopathy. Duration of
atrial fibrillation ,24 h and normal left atrial size were also
associated with early recovery of atrial function (7).
Relation between left atrial dysfunction and thromboem-
bolic complications. Thromboemboli are known to occur after
cardioversion in nonanticoagulated patients despite “negative”
transesophageal echocardiograms immediately before cardio-
version (8,9). It is most likely that persistent or increased atrial
stasis after cardioversion results in the formation of fresh,
loosely adherent thrombi and subsequent embolism. Lack of
mechanical activity contributes to stasis in the left atrium (10).
In view of the excellent sensitivity and specificity of transesoph-
ageal echocardiography for detection of left atrial appendage
clots (11), it is unlikely that these events are related to small,
preexistent clots missed by the precardioversion transesopha-
geal echocardiogram. The occurrence of embolism in up to 7%
of patients undergoing cardioversion (8,12,13), the close tem-
poral relation between the embolic event and the procedure
and, oftentimes, the paucity of other potential sources of
embolism (8,9) greatly undermine the role of other sources of
embolism. Thus, an increase in the thrombogenic milieu seems
to occur immediately after cardioversion, and patients are
predisposed to atrial thrombus formation, presumably until
such time as “normal” atrial and atrial appendage function
resumes.
Current recommendations for anticoagulation and clinical
implications of our findings. Anticoagulation for 2 to 4 weeks
before cardioversion is currently recommended to allow for
adherence and endothelialization or resolution of existing
thrombi, as well as to prevent new clot formation. In addition,
anticoagulation for up to 4 weeks after cardioversion is recom-
mended to allow for late resumption of atrial activity (1,8).
Recent studies have proposed the use of transesophageal
echocardiography to screen patients for atrial thrombi before
cardioversion (14,15) to reduce the requirement for prolonged
anticoagulation before cardioversion. It is believed that in
patients who have no demonstrable left atrial thrombi on
transesophageal echocardiography before cardioversion, long-
term anticoagulation before cardioversion may be deferred
(15). Existing reports, however, clearly support the use of
anticoagulation for a period after cardioversion (8,9).
To minimize the cost and potential morbidity associated
with anticoagulation, future research should focus on identify-
ing subsets of patients who do not need prolonged anticoagu-
lation after cardioversion. Studies reporting on the duration of
atrial mechanical dysfunction after cardioversion will be the
basis for such trials. However, because most left atrial thrombi
reside in the left atrial appendage (16), before any strategy of
short-term postcardioversion anticoagulation relying on the
recovery of atrial mechanical function is evaluated, it needs to
be demonstrated that left atrial mechanical function is an
accurate surrogate marker of left atrial appendage mechanical
function. Although this may intuitively seem to be so, it has not
yet been documented. If EMAF is indeed a surrogate marker
of atrial appendage function, clinical rationale would indicate
that the duration of anticoagulation be shortened in patients
who show early recovery of EMAF. Clearly, these implications
apply only to those patients who remain in sinus rhythm after
cardioversion.
The findings of our study also have a potential impact on
predicting improvement in exercise capacity after cardiover-
sion in symptomatic patients with atrial fibrillation. It is well
described that improvement in symptom-limited maximal ox-
ygen consumption and anaerobic threshold is delayed and does
not occur immediately after cardioversion (17). This has been
ascribed to the delay in improvement in stroke volume that
follows an increased atrial contribution to left ventricular
filling. Our findings imply that patients undergoing electrical
cardioversion may have delayed improvement in exercise
capacity after cardioversion compared with those patients who
cardiovert spontaneously or pharmacologically.
Study limitations. Several factors other than atrial function
can influence the peak velocity of the atrial filling wave. These
include the loading conditions of the heart, ventricular com-
pliance, heart rate and appropriate placement of the sample
volume. Therefore, the peak velocity of the atrial filling wave
is, at best, an indirect and less than ideal way of assessing atrial
function. Precautions were taken, however, to minimize tech-
nical sampling errors and to ensure standardization of mea-
surements. We also reviewed the medical records of enrolled
patients to look for any major events during the study period
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that could possibly have influenced the peak velocity of the
atrial filling wave, independent of atrial function. No major
hemodynamic changes that could potentially affect recovery of
EMAF were seen in our group during the study period.
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